
Kaire Innos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7238400/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology, 2019, 5, 1749.	7.1	1,691
2	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
3	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. JAMA Oncology, 2018, 4, 1553.	7.1	1,260
4	Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 980-1004.	13.7	1,230
5	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	13.7	786
6	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	13.7	571
7	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.7	461
8	The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 42-54.	8.1	390
9	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 913-933.	8.1	259
10	Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2191-2205.	2.8	205
11	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncology, The, 2019, 20, 1211-1225.	10.7	199
12	Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. Eurosurveillance, 2017, 22, .	7.0	100
13	On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2158-2168.	2.8	93
14	Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2179-2190.	2.8	80
15	Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2008, 111, 531-540.	2.5	39
16	Recent trends and racial/ethnic differences in the incidence and treatment of ductal carcinoma in situ of the breast in California women. Cancer, 2003, 97, 1099-1106.	4.1	35
17	Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014. BMC Cancer, 2018, 18, 1075.	2.6	33
18	Sex differences in cancer survival in Estonia: a population-based study. BMC Cancer, 2015, 15, 72.	2.6	31

KAIRE INNOS

#	Article	IF	CITATIONS
19	Identifying women at risk for delayed presentation of breast cancer: a cross-sectional study in Estonia. BMC Public Health, 2013, 13, 947.	2.9	30
20	Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: AÂEUROCARE-5 study. European Journal of Cancer, 2017, 84, 335-353.	2.8	29
21	Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer. International Journal of Cancer, 2019, 144, 2118-2127.	5.1	27
22	Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study. Acta Oncológica, 2017, 56, 52-58.	1.8	23
23	Divergent trends in lung cancer incidence by gender, age and histological type in Estonia: a nationwide population-based study. BMC Cancer, 2017, 17, 596.	2.6	18
24	Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis?. European Journal of Cancer, 2018, 93, 127-137.	2.8	18
25	Cancer patient survival in Estonia 1995–2009: Time trends and data quality. Cancer Epidemiology, 2014, 38, 253-258.	1.9	17
26	Cancer incidence and cause-specific mortality in male and female physicians: a cohort study in Estonia. Scandinavian Journal of Public Health, 2002, 30, 133-140.	2.3	16
27	Time trends in population-based breast cancer survival in Estonia: Analysis by age and stage. Acta Oncológica, 2014, 53, 226-234.	1.8	15
28	Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine. BMJ Open, 2019, 9, e031856.	1.9	14
29	The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer. BioMed Research International, 2018, 2018, 1-8.	1.9	13
30	Place of residence predicts breast cancer stage at diagnosis in Estonia. European Journal of Public Health, 2011, 21, 376-380.	0.3	12
31	Childhood cancer incidence and survival trends in Estonia (1970–2016): a nationwide population-based study. BMC Cancer, 2020, 20, 30.	2.6	12
32	Subsite- and stage-specific colorectal cancer trends in Estonia prior to implementation of screening. Cancer Epidemiology, 2018, 52, 112-119.	1.9	11
33	Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016. Acta Oncológica, 2019, 58, 1549-1556.	1.8	11
34	Increasing kidney cancer incidence and survival in Estonia: role of age and stage. Acta Oncológica, 2019, 58, 21-28.	1.8	11
35	Survival for colon and rectal cancer in Estonia: Role of staging and treatment. Acta Oncológica, 2012, 51, 521-527.	1.8	10
36	Age-specific cancer survival in Estonia: recent trends and data quality. Clinical Epidemiology, 2015, 7, 355.	3.0	9

KAIRE INNOS

#	Article	IF	CITATIONS
37	Prostate cancer incidence, mortality and survival trends in Estonia, 1995–2014. Scandinavian Journal of Urology, 2017, 51, 442-449.	1.0	9
38	Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. European Journal of Surgical Oncology, 2020, 46, 1151-1159.	1.0	9
39	Human papillomavirus self-sampling for long-term non-attenders in cervical cancer screening: A randomised feasibility study in Estonia. Journal of Medical Screening, 2022, 29, 53-60.	2.3	9
40	The impact of under-reporting of cases on the estimates of childhood cancer incidence and survival in Estonia. European Journal of Cancer Prevention, 2017, 26, S147-S152.	1.3	7
41	Gastric cancer trends in Estonia 1995–2014 by age, subsite, morphology and stage. Acta Oncológica, 2019, 58, 283-289.	1.8	7
42	Incidence and Survival for Head and Neck Cancers in Estonia, 1996–2016: A Population-Based Study. Clinical Epidemiology, 2021, Volume 13, 149-159.	3.0	7
43	Recent changes in breast cancer incidence and mortality in Estonia: Transition to the west. Acta Oncológica, 2016, 55, 728-733.	1.8	5
44	Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet). Oral Oncology, 2020, 108, 104766.	1.5	5
45	Time Trends in Ovarian Cancer Survival in Estonia by Age and Stage. International Journal of Gynecological Cancer, 2017, 27, 44-49.	2.5	4
46	Quality assurance in melanoma care: The EU-MELACARE study. European Journal of Surgical Oncology, 2018, 44, 1773-1778.	1.0	3
47	Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades. Cancer Epidemiology, 2019, 62, 101566.	1.9	3
48	Changes in therapy and survival of metastatic renal cell carcinoma in Estonia. BMC Cancer, 2020, 20, 201.	2.6	3
49	Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study. Digestive and Liver Disease, 2021, 53, 639-645.	0.9	3
50	Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. Breast Cancer Research and Treatment, 2020, 183, 439-450.	2.5	2
51	The impact of sociodemographic factors on the utilization of radiation therapy in breast cancer patients in Estonia: a register-based study. International Journal for Equity in Health, 2021, 20, 152.	3.5	2
52	Mammography use and mode of detection among breast cancer patients in Estonia. Women and Health, 2016, 56, 129-140.	1.0	1
53	Changes in the quality of care of colorectal cancer in Estonia: a population-based high-resolution study. BMJ Open, 2020, 10, e035556.	1.9	1
54	Stage-specific survival differences between colon cancer subsites: a population-based study. Acta Oncológica, 2021, 60, 1702-1705.	1.8	1